← Eichor
Study identifier: NCT07179159 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

Condition: HELICOBACTER PYLORI INFECTIONS  ·  Sponsor: Yanqing Li

PhaseNA
Planned participants372
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This study is a multicentre, non-inferiority randomized controlled trial to compare the efficacy and safety of 14-day vonoprazan-based dual therapy with versus quadruple therapy for the eradication of Helicobacter pylori. The primary outcome is eradication rate, and the secondary outcome includes the incidence of adverse events and compliance.

This description comes directly from the study's public registry record.

Talk to the study team

Yueyue Li  ·  +8618560089751  ·  lyynqj@126.com

Always discuss trial participation with your own doctor first.

Locations (2)

Qilu Hospital of Shandong UniversityJinan, Shandong, ChinaRecruiting
Qilu Hospital of Shandong UniversityJinan, ChinaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07179159